Difference between revisions of "Small cell lung cancer - null regimens"
Jump to navigation
Jump to search
(Created page with "The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight in...") |
Warner-admin (talk | contribs) m (Text replacement - "https://ascopubs.org/doi/full/10.1200" to "https://doi.org/10.1200") |
||
| Line 50: | Line 50: | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
|- | |- | ||
| − | |[https:// | + | |[https://doi.org/10.1200/JCO.2001.19.8.2114 Schiller et al. 2001 (ECOG E7593)] |
| style="background-color:#1a9851" |Phase III (C) | | style="background-color:#1a9851" |Phase III (C) | ||
|Topotecan | |Topotecan | ||
| Line 74: | Line 74: | ||
# Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, Tschetter LK, Kardinal CG, Twito DI, Levitt R, Gerstner JB. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol. 1994 Nov;12(11):2321-6. [https://ascopubs.org/doi/abs/10.1200/JCO.1994.12.11.2321 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7964947 PubMed] | # Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, Tschetter LK, Kardinal CG, Twito DI, Levitt R, Gerstner JB. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol. 1994 Nov;12(11):2321-6. [https://ascopubs.org/doi/abs/10.1200/JCO.1994.12.11.2321 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7964947 PubMed] | ||
# van Zandwijk N, Groen HJ, Postmus PE, Burghouts JT, ten Velde GP, Ardizzoni A, Smith IE, Baas P, Sahmoud T, Kirkpatrick A, Dalesio O, Giaccone G. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer: a randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1997 Oct;33(11):1759-66. [https://www.ejcancer.com/article/S0959-8049(97)00174-3/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9470829 PubMed] | # van Zandwijk N, Groen HJ, Postmus PE, Burghouts JT, ten Velde GP, Ardizzoni A, Smith IE, Baas P, Sahmoud T, Kirkpatrick A, Dalesio O, Giaccone G. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer: a randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1997 Oct;33(11):1759-66. [https://www.ejcancer.com/article/S0959-8049(97)00174-3/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9470829 PubMed] | ||
| − | # '''ECOG E7593:''' Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Apr 15;19(8):2114-22. [https:// | + | # '''ECOG E7593:''' Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Apr 15;19(8):2114-22. [https://doi.org/10.1200/JCO.2001.19.8.2114 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11304763 PubMed] |
# Hanna NH, Sandier AB, Loehrer PJ Sr, Ansari R, Jung SH, Lane K, Einhorn LH. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol. 2002 Jan;13(1):95-102. [https://academic.oup.com/annonc/article/13/1/95/143629 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11863118 PubMed] | # Hanna NH, Sandier AB, Loehrer PJ Sr, Ansari R, Jung SH, Lane K, Einhorn LH. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol. 2002 Jan;13(1):95-102. [https://academic.oup.com/annonc/article/13/1/95/143629 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11863118 PubMed] | ||
| − | # '''CALGB 30504:''' Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20;33(15):1660-5. Epub 2015 Mar 2. [https:// | + | # '''CALGB 30504:''' Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20;33(15):1660-5. Epub 2015 Mar 2. [https://doi.org/10.1200/JCO.2014.57.3105 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429175/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25732163 PubMed] |
==Placebo== | ==Placebo== | ||
| Line 90: | Line 90: | ||
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]] | ! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
| − | |[https:// | + | |[https://doi.org/10.1200/JCO.2002.02.108 Shepherd et al. 2002] |
| style="background-color:#1a9851" |Phase III (C) | | style="background-color:#1a9851" |Phase III (C) | ||
|Marimastat | |Marimastat | ||
| Line 98: | Line 98: | ||
''No further antineoplastic treatment.'' | ''No further antineoplastic treatment.'' | ||
===References=== | ===References=== | ||
| − | # Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol. 2002 Nov 15;20(22):4434-9. [https:// | + | # Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol. 2002 Nov 15;20(22):4434-9. [https://doi.org/10.1200/JCO.2002.02.108 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12431965 PubMed] |
=Relapsed or refractory disease= | =Relapsed or refractory disease= | ||
Revision as of 17:54, 7 March 2020
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main SCLC page for current regimens.
Limited stage, consolidation after upfront therapy
Observation
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Kelly et al. 1995 | Phase III (C) | IFN alfa-2a | Did not meet primary endpoint of OS |
No further treatment.
Preceding treatment
- Chemoradiotherapy
References
- Kelly K, Crowley JJ, Bunn PA Jr, Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin S, Livingston R. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol. 1995 Dec;13(12):2924-30. link to original article PubMed
Extensive stage, maintenance after first-line therapy
Observation
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Jett et al. 1994 | Phase III (C) | IFN gamma | Did not meet primary endpoint of OS |
| van Zandwijk et al. 1997 | Phase III (C) | IFN gamma | Did not meet primary endpoint of OS |
| Schiller et al. 2001 (ECOG E7593) | Phase III (C) | Topotecan | Did not meet primary endpoint of OS50% |
| Hanna et al. 2002 | Phase III (C) | Etoposide | Might have inferior OS |
| Ready et al. 2015 (CALGB 30504) | Randomized Phase II (C) | Sunitinib | Seems to have inferior PFS |
No further treatment.
Preceding treatment
- ECOG E7593: Cisplatin & Etoposide x 4
- CALGB 30504: Carboplatin & Etoposide or Cisplatin & Etoposide for 4 to 6 cycles
References
- Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, Tschetter LK, Kardinal CG, Twito DI, Levitt R, Gerstner JB. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol. 1994 Nov;12(11):2321-6. link to original article PubMed
- van Zandwijk N, Groen HJ, Postmus PE, Burghouts JT, ten Velde GP, Ardizzoni A, Smith IE, Baas P, Sahmoud T, Kirkpatrick A, Dalesio O, Giaccone G. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer: a randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1997 Oct;33(11):1759-66. link to original article PubMed
- ECOG E7593: Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Apr 15;19(8):2114-22. link to original article PubMed
- Hanna NH, Sandier AB, Loehrer PJ Sr, Ansari R, Jung SH, Lane K, Einhorn LH. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol. 2002 Jan;13(1):95-102. link to original article PubMed
- CALGB 30504: Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20;33(15):1660-5. Epub 2015 Mar 2. link to original article link to PMC article contains verified protocol PubMed
Placebo
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Shepherd et al. 2002 | Phase III (C) | Marimastat | Did not meet primary endpoint of OS |
No further antineoplastic treatment.
References
- Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol. 2002 Nov 15;20(22):4434-9. link to original article PubMed
Relapsed or refractory disease
Best supportive care
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| O'Brien et al. 2006 | Phase III (C) | Oral topotecan | Seems to have inferior OS |
No active antineoplastic treatment.
References
- O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006 Dec 1;24(34):5441-7. link to original article contains verified protocol PubMed